Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ZSVG-02-O COVID-19 mRNA Vaccine in Healthy Adults
NCT06113731Phase 2Recruiting
- Sponsor
- Virogin Biotech
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZSVG-02-O in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Virogin Biotech. Primary endpoints: Geometric Mean Titre (GMT) of Neutralizing Antibodies against SARS-CoV-2 and 4-fold increasing rate of Neutralizing Antibodies against SARS-CoV-2. Started Jul 2023; status: recruiting.
02
Drugs
ZSVG-02-O
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06113731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113731.